Infantile suprasellar tumor diagnosed as a pineoblastoma RB1 subgroup and treatment challenges: A pediatric SNO Molecular Tumor Board
Neurooncol Adv
.
2022 Jun 14;4(1):vdac092.
doi: 10.1093/noajnl/vdac092.
eCollection 2022 Jan-Dec.
Authors
Jeffrey A Rubens
1
,
Craig Erker
2
,
Holly Lindsay
3
,
Ben Ho
4
,
Bryan Li
4
,
Eric Bouffet
4
,
Alan Cohen
5
,
Charles Eberhart
6
,
Birgit Ertl-Wagner
7
,
Anita Mahajan
8
,
Stergios Zacharoulis
9
,
Annie Huang
4
,
Roger Packer
10
Affiliations
1
Division of Pediatric Oncology, Sidney Kimmel Comprehensive Cancer Center, School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.
2
Division of Hematology/Oncology, Department of Paediatrics, IWK Health Centre and Dalhousie University, Halifax, Nova Scotia, Canada.
3
Division of Pediatric Hematology and Oncology, Department of Pediatrics, Texas Children's Hospital/Baylor College of Medicine, Houston, Texas, USA.
4
Division of Hematology/Oncology, Department of Pediatrics, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada.
5
Division of Neurosurgery, School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.
6
Division of Pathology, School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.
7
Division of Neuroradiology, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada.
8
Department of Radiation Oncology, Mayo Clinic, Rochester, MN, USA.
9
Department of Pediatrics, Columbia University Irving Medical Center, New York, New York, USA.
10
The Brain Tumor Institute, Center for Neuroscience and Behavioral Medicine, Children's National Health System, Washington, DC, USA.
PMID:
35821675
PMCID:
PMC9268732
DOI:
10.1093/noajnl/vdac092
No abstract available
Keywords:
RB1; intrathecal topotecan; metronomic therapy; pineoblastoma.